Changes in Vascular Distensibility during Angiotensin-Converting Enzyme Inhibition Involve Bradykinin Type 2 Receptors

Journal of Vascular Research

Volumn 41, Issue 1, 2004, Pages 18-27

  Aartsen, Wendy M ^a   Hilgers, R H P ^a   Schiffers, P M H ^a   Daemen, M J A P ^a   De Mey, J G R ^a   Smits, J F M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bradykinin type 2 receptor antagonism; Membrane bound angiotensin converting enzyme, deficiency; Vascular distensibility

Indexed keywords

BRADYKININ B2 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY PRESSURE; ENZYME INHIBITION; ENZYME REGULATION; FETUS DEVELOPMENT; HYPOTHESIS; INTERNAL CAROTID ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; RIGIDITY; SPECIES COMPARISON;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA; ARTERIES; BLOOD PRESSURE; BRADYKININ; CAROTID ARTERIES; FEMALE; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, BRADYKININ B2;

EID: 1542362550     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076125     Document Type: Article

References (33)

1. Lee RMKW, Berecek KH, Tsoporis J, McKenzie R, Triggle CR: Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991;17:141-150.
2. Rizzoni D, Porteri E, Piccoli A, Castellano M, Bettoni G, Muiescan ML, Pasini G, Guelfi D, Mulvany MJ, Rosei EA: Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 1998;32:305-310.
3. Safar ME, Bortel LMAB van, Struijker-Boudier HAJ: Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vasc Res 1996;34:67-81.
4. Ben Driss A, Himbert C, Poitevin P, Duriez M, Michel JB, Levy BI: Enalapril improves arterial elastic properties in rats with myocardial infarction. J Cardiovasc Pharmacol 1999;34:102-107.
5. Goto K, Fujii K, Onaka U, Abe I, Fujishima M: Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 2000;36:575-580.
6. Mulder P, Elfertak L, Richard V, Compagnon P, Devaux B, Henry JP, Scalbert E, Desché P, Macé B, Thuillez C: Peripheral artery structure and endothelial function in heart failure effect of ACE inhibition. Am J Physiol 1996;271:H469-H477.
7. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HR, Uprichard ACG, Pepine CJ, Pitt B: Angiotensin-converting enzyme inhibition with Quinapril improves endothelial vasomotor dysfunction artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996;94:258-265.
8. Vaughan DE: Angiotensin and vascular fibrinolytic balance. Am J Hypertens 2002;15:3S-8S.
9. Charpiot P, Holland PH, Figgi A, Piquet P, Scalbert E, Bodard H, Barlatier A, Latrille V, Trannier P, Mercier C, Luccioni R, Calaf R, Garçon D: ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler Thromb 1993;13:1125-1138.
10. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, Dzau VJ: Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation. Evidence for tissue angiotensin-converting enzyme function. Arterioscler Thromb Vasc Biol 2000;20:915-922.
11. Hosomi N, Mizushige K, Ohyama H, Takahashi T, Kitadai M, Hatanaka Y, Matsuo H, Kohno M, Koziol JA: Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001;32:1539-1545.
12. Park JB, Intengan HD, Schiffrin EL: Reduction of resistance artery stiffness by treatment with AT1-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst 2000;1:40-45.
13. Esther CR Jr, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE: The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997;99:2375-2385.
14. Suylen RJ, Aartsen WM, Smits JFM, Daemen MJAP: Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. Am J Respir Crit Care Med 2001;163:1241-1245.
15. Bao G, Qadri F, Stauss B, Stauss H, Gohlke P, Unger T: HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur J Pharmacol 1991;200:179-182.
16. Schiffers PMH, Henrion D, Boulanger CM, Colucci-Guyon E, Langa-Vuves F, Essen H van, Fazzi GE, Lévy BI, De Mey JGR: Altered flow-induced arterial remodeling on vimentin-deficient mice. Arterioscl Thromb Vasc Biol 2000;20:611-616.
17. Dolber PC, Spach MS: Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment. Stain Technol 1987;62:23-26.
18. Ceiler DL, Nelissen-Vrancken HJMG, Smits JFM, De Mey JGR: Pressure but not angiotensin II-induced increases in wall mass or tone influences static and dynamic aorta mechanics. J Hypertens 1999;17:1109-1116.
19. Pourageaud F, Freslon JL: Effects of nitric oxide and sodium nitroprusside on the intrinsic elastic properties of pressurized rat coronary artery. Fundam Clin Pharmacol 1996;10:136-143.
20. Bergel DH: The static elastic properties of the arterial wall. J Physiol 1961;156:445-457.
21. Schütz S, Le Moullec JM, Corvol P, Gasc JM: Early expression of all components of the renin-angiotensin system in human development. Am J Pathol 1996;149:2067-2079.
22. Lumbers ER: Functions of the renin-angiotensin system during development. Clin Exp Pharmacol Physiol 1995;22:499-505.
23. Safar E: Carotid artery stiffness with applications to cardiovascular pharmacology. Gen Pharmacol 1996;27:1293-1302.
24. Levy BI, Michel JB, Salzmann JL, Poitevin P, Devissaguet M, Scalbert ME, Safar ME: Long-term effects of angiotensin-converting enzyme inhibition on the arterial wall of adult spontaneously hypertensive rats. Am J Cardiol 1993;71:8e-16e.
25. Baumbach GL, Sigmund CD, Faraci FM: Cerebral arteriolar structure in mice overexpressing human renin and angiotensinogen. Hypertension 2003;41:50-55.
26. Hajdu MA, Heistad DD, Baumbach GL: Effects of antihypertensive therapy on mechanics of cerebral arterioles in rats. Hypertension 1991;17:308-316.
27. Safar ME, Levy BI: The effect of hypertension and ACE inhibition on arterial structure and compliance. Clin Exp Pharmacol Physiol 1992;19(suppl 19):29-32.
28. Henriksen EJ, Jacob S, Fogt DL, Dietze GJ: Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance. Am J Physiol 1998;275:R40-R45.
29. Henriksen EJ, Jacob S, Kinnick TR, Youngblood EB, Schnit MB, Dietze GJ: ACE inhibition and glucose transport in insulin-resistant muscle: Roles of bradykinin and nitric oxide. Am J Physiol 1999;277:R332-R336.
30. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Anania V, Glorioso N: Early blockade of bradykinin B2-receptors alters the adult cardiovascular phenotype in rats. Hypertension 1995;25:453-459.
31. Bézie Y, Lamazière JMD, Laurent S, Challande P, Sa Cunha R, Bonnet J, Lacolley P: Fibronectin expression and aortic wall elastic modulus in spontaneously hypertensive rats. Arterioscl Thromb Vasc Biol 1998;18:1027-1034.
32. Brown NJ, Gainer JV, Stein CM, Vaughan DE: Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999;33:1431-1435.
33. Brown NJ, Gainer JV, Murphey LJ, Vaughan DE: Bradykinin stimulates plasminogen activator release from human forearm vasculature through B2 receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000;102:2190-2196.